BioNTech Acquires Chinese Oncology Firm Biotheus for $950M

The Care and Protection of Children Trust

CPCT Launches Groundbreaking Initiative to Provide Lifelong Free Treatment for Children with Spinal Muscular Atrophy (SMA) in Karnataka

Early Comprehensive Genomic Profiling Improves Cancer Treatment Outcomes, Study Shows

EMA Reverses Decision, Recommends Limited Approval for Eisai and Biogen’s Alzheimer’s Drug Leqembi

Exact Sciences Unveils Advances in Multi-Cancer Early Detection with Cancerguard™ Test

MSD and LaNova Medicines Enter Exclusive Global License Agreement for Novel Cancer Therapy, LM-299

Promising CAR T Cell Therapies from BMS and Cabaletta Bio Show Potential for Durable Remission in Severe Lupus

FDA Grants Accelerated Approval to PTC Therapeutics' KEBILIDI™, the First Gene Therapy for AADC Deficiency in the U.S.

Association for Molecular Pathology Publishes Joint Consensus Report on SARS-CoV-2 Genomic Surveillance for Hospitals and Public Health Laboratories

Philips India Unveils Advanced Azurion Imaging System to Revolutionize Cardiac and Neurovascular Care

Tempus AI Study Highlights Benefits of Dual RNA and DNA Sequencing for Advanced Lung Cancer

Ontada and Datavant Partner to Expand Access to Real-World Oncology Data for Accelerated Cancer Innovation

Tempus AI and Flatiron Health Partner to Integrate Genomic Testing into OncoEMR for Enhanced Oncology Care

Flare Therapeutics and Roche Forge Strategic Partnership to Discover Precision Oncology Therapies Targeting Transcription Factors

FDA Approves Autolus’s CAR-T Therapy Aucatzyl for Relapsed or Refractory B-ALL in Adults

Home
/
update
/
details

NImmune and BioTherapeutics Collaborate to Advance Precision Medicine Development

NextEdge Admin

07 Sep 2024

2 min 17 sec

NImmune Biopharma has partnered with BioTherapeutics to advance the development of precision medicines in inflammation and immunology. This collaboration will strengthen NImmune's capabilities in precision immunology by leveraging BioTherapeutics’ preclinical expertise and regulatory support.

The partnership will provide NImmune access to BioTherapeutics' advanced animal models, including pig models for inflammatory bowel disease, as well as pharmacokinetics/pharmacodynamics analysis and specialized regulatory infrastructure. These resources will support mechanism of action validation studies and the development of both animal and computational models for autoimmune and inflammatory diseases.

Dr. Raquel Hontecillas, BioTherapeutics' chief scientific officer, expressed excitement about the collaboration, emphasizing the value of combining computational and preclinical services with proprietary animal models to accelerate the development of needed therapeutics. She highlighted the efficient drug development ecosystem in Blacksburg, which fosters rapid and safe therapeutic advancements.

This new partnership builds on NImmune's ongoing collaboration with the NIMML Institute, creating a robust scientific innovation ecosystem. The ecosystem has already led to notable successes, such as the development of NX-13, which was acquired by AbbVie.

NImmune’s CEO, Dr. Josep Bassaganya-Riera, emphasized the importance of this partnership, noting how it enhances the company’s ability to create effective immunoregulatory therapies for patients with unmet needs in inflammatory and autoimmune diseases. Through strategic partnerships with BioTherapeutics and the NIMML Institute, NImmune is accelerating its pipeline from AI-driven target discovery using the TITAN-X platform to clinical testing and commercialization.